Elevara Medicines
London, England, United Kingdom · Biotechnology, Health Care · 13 employees
Elevara Medicines is a clinical-stage biotech company focused on developing therapies for rheumatoid arthritis (RA) and chronic inflammatory diseases. The company's lead program, ELV001, is an innovative oral CDK4/6 inhibitor that targets synovial fibroblasts, aiming to disrupt traditional treatment paradigms. Elevara's goal is to provide effective options for patients who do not achieve disease r
Funding history
- Series A · $70.0M · Oct 2025
Recent signals
- Jul 14, 2026: Elevara Medicines Appoints Dr. Mai-Britt Zocca as Chief Executive Officer
- Oct 22, 2025: Raised $70.0M in Series A
See plans & pricing → Track Elevara Medicines’s funding, hiring and signals, with verified contacts, on Fundz.
Fundz watches Elevara Medicines across 18 signal types, from funding and M&A to exec moves and hiring.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.